ScreenerHero

MAZE Maze Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · mazetx.com
26.25USD-0.68%Mkt Cap: 1.46B $P/E: —

Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, …

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap1.46B USD
Enterprise Value1.12B USD
Revenue (TTM)20.00M USD
Gross Profit20.00M USD
Net Income (TTM)-131.12M USD
Revenue/Share0.38 USD
Last Price26.25 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees141
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-8.01
PEG—
EV/EBITDA-7.78
EV/Revenue55.88
P/S73.41
P/B3.24
EPS (TTM)-2.48
EPS (Forward)-3.30
52W Range
21.9514% of range53.65
52W High53.65 USD
52W Low21.95 USD
Profitability
Gross Margin100.00%
Oper. Margin-728.06%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-36.94%
ROA-33.02%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-111.94M USD
CapEx (TTM)794.00K USD
FCF Margin-318.14%
FCF Yield-4.36%
Net Debt-350.66M USD
Net Debt/EBITDA2.44
Balance Sheet
Debt/Equity0.07
Current Ratio18.31
Quick Ratio18.03
Book Value/Sh8.16 USD
Cash/Share7.40 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.1 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)61.50 USD
Upside (mean)+134.3%
Target Range46.00 USD – 110.00 USD
46.00+134.3% to mean110.00
# Analysts12
Ownership
Shares Out.55.55M
Float36.80M
Insiders1.53%
Institutions106.86%
Short Interest
Short Ratio12.3d
Short % Float11.51%
Short % Out.10.22%
Shares Short5.68M
Short (prev mo.)5.99M
Technical
SMA 5026.98 (-2.7%)
SMA 20032.92 (-20.3%)
Beta—
S&P 52W Chg16.45%
Avg Vol (30d)754.05K
Avg Vol (10d)1.12M
Technical Indicators
RSI (14)49.4
MACD-0.0133
MACD Signal-0.1710
MACD Hist.+0.1577
BB Upper29.06 USD
BB Middle25.63 USD
BB Lower22.20 USD
BB Width26.75%
ATR (14)1.581 USD
Vol Ratio (20d)0.90x